Stryker Net Income Growth & History (SYK)
Stryker's net income was $3.25B for fiscal 2025.
View full Stryker company overviewStryker annual net income history
| Fiscal year | Period ended | Net income | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $3.25B | $253.0M | +8.45% |
| 2024 | 2024-12-31 | $2.99B | −$172.0M | −5.43% |
| 2023 | 2023-12-31 | $3.17B | $807.0M | +34.22% |
| 2022 | 2022-12-31 | $2.36B | $364.0M | +18.25% |
| 2021 | 2021-12-31 | $1.99B | $395.0M | +24.70% |
| 2020 | 2020-12-31 | $1.60B | −$484.0M | −23.24% |
| 2019 | 2019-12-31 | $2.08B | −$1.47B | −41.37% |
| 2018 | 2018-12-31 | $3.55B | $2.53B | +248.33% |
| 2017 | 2017-12-31 | $1.02B | −$627.0M | −38.07% |
| 2016 | 2016-12-31 | $1.65B | $208.0M | +14.45% |
| 2015 | 2015-12-31 | $1.44B | $924.0M | +179.42% |
| 2014 | 2014-12-31 | $515.0M | −$491.0M | −48.81% |
| 2013 | 2013-12-31 | $1.01B | −$292.0M | −22.50% |
| 2012 | 2012-12-31 | $1.30B | −$47.0M | −3.49% |
| 2011 | 2011-12-31 | $1.34B | $72.0M | +5.66% |
| 2010 | 2010-12-31 | $1.27B | $166.0M | +15.00% |
| 2009 | 2009-12-31 | $1.11B | −$40.8M | −3.55% |
| 2008 | 2008-12-31 | $1.15B | $130.4M | +12.82% |
| 2007 | 2007-12-31 | $1.02B | — | — |
Stryker quarterly net income
| Fiscal quarter | Period ended | Net income | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $1.28B | $392.0M | +44.34% |
| Q1 2026 | 2026-03-31 | $745.0M | $91.0M | +13.91% |
| Q4 2025 | 2025-12-31 | $849.0M | $303.0M | +55.49% |
| Q3 2025 | 2025-09-30 | $859.0M | $25.0M | +3.00% |
| Q2 2025 | 2025-06-30 | $884.0M | $59.0M | +7.15% |
| Q1 2025 | 2025-03-31 | $654.0M | −$134.0M | −17.01% |
| Q4 2024 | 2024-12-31 | $546.0M | −$597.0M | −52.23% |
| Q3 2024 | 2024-09-30 | $834.0M | $142.0M | +20.52% |
| Q2 2024 | 2024-06-30 | $825.0M | $87.0M | +11.79% |
| Q1 2024 | 2024-03-31 | $788.0M | $196.0M | +33.11% |
| Q4 2023 | 2023-12-31 | $1.14B | $580.0M | +103.02% |
| Q3 2023 | 2023-09-30 | $692.0M | −$124.0M | −15.20% |
| Q2 2023 | 2023-06-30 | $738.0M | $82.0M | +12.50% |
| Q1 2023 | 2023-03-31 | $592.0M | $269.0M | +83.28% |
| Q4 2022 | 2022-12-31 | $563.0M | −$99.0M | −14.95% |
| Q3 2022 | 2022-09-30 | $816.0M | $378.0M | +86.30% |
| Q2 2022 | 2022-06-30 | $656.0M | $64.0M | +10.81% |
| Q1 2022 | 2022-03-31 | $323.0M | $21.0M | +6.95% |
| Q4 2021 | 2021-12-31 | $662.0M | $94.0M | +16.55% |
| Q3 2021 | 2021-09-30 | $438.0M | −$183.0M | −29.47% |
| Q2 2021 | 2021-06-30 | $592.0M | $675.0M | — |
| Q1 2021 | 2021-03-31 | $302.0M | −$191.0M | −38.74% |
| Q4 2020 | 2020-12-31 | $568.0M | −$157.0M | −21.66% |
| Q3 2020 | 2020-09-30 | $621.0M | $155.0M | +33.26% |
| Q2 2020 | 2020-06-30 | −$83.0M | −$563.0M | — |
| Q1 2020 | 2020-03-31 | $493.0M | $81.0M | +19.66% |
| Q4 2019 | 2019-12-31 | $725.0M | −$1.34B | −64.94% |
| Q3 2019 | 2019-09-30 | $466.0M | −$124.0M | −21.02% |
| Q2 2019 | 2019-06-30 | $480.0M | $28.0M | +6.19% |
| Q1 2019 | 2019-03-31 | $412.0M | −$31.0M | −7.00% |
| Q4 2018 | 2018-12-31 | $2.07B | $2.32B | — |
| Q3 2018 | 2018-09-30 | $590.0M | $156.0M | +35.94% |
| Q2 2018 | 2018-06-30 | $452.0M | $61.0M | +15.60% |
| Q1 2018 | 2018-03-31 | $443.0M | −$1.0M | −0.23% |
| Q4 2017 | 2017-12-31 | −$249.0M | −$759.0M | — |
| Q3 2017 | 2017-09-30 | $434.0M | $79.0M | +22.25% |
| Q2 2017 | 2017-06-30 | $391.0M | $11.0M | +2.89% |
| Q1 2017 | 2017-03-31 | $444.0M | $42.0M | +10.45% |
| Q4 2016 | 2016-12-31 | $510.0M | −$12.0M | −2.30% |
| Q3 2016 | 2016-09-30 | $355.0M | $54.0M | +17.94% |
| Q2 2016 | 2016-06-30 | $380.0M | −$12.0M | −3.06% |
| Q1 2016 | 2016-03-31 | $402.0M | $178.0M | +79.46% |
| Q4 2015 | 2015-12-31 | $522.0M | $262.0M | +100.77% |
| Q3 2015 | 2015-09-30 | $301.0M | $244.0M | +428.07% |
| Q2 2015 | 2015-06-30 | $392.0M | $264.0M | +206.25% |
| Q1 2015 | 2015-03-31 | $224.0M | $154.0M | +220.00% |
| Q4 2014 | 2014-12-31 | $260.0M | −$126.0M | −32.64% |
| Q3 2014 | 2014-09-30 | $57.0M | −$46.0M | −44.66% |
| Q2 2014 | 2014-06-30 | $128.0M | −$85.0M | −39.91% |
| Q1 2014 | 2014-03-31 | $70.0M | −$234.0M | −76.97% |
| Q4 2013 | 2013-12-31 | $386.0M | $116.0M | +42.96% |
| Q3 2013 | 2013-09-30 | $103.0M | −$250.0M | −70.82% |
| Q2 2013 | 2013-06-30 | $213.0M | −$112.0M | −34.46% |
| Q1 2013 | 2013-03-31 | $304.0M | −$46.0M | −13.14% |
| Q4 2012 | 2012-12-31 | $270.0M | −$131.0M | −32.67% |
| Q3 2012 | 2012-09-30 | $353.0M | $26.0M | +7.95% |
| Q2 2012 | 2012-06-30 | $325.0M | $16.0M | +5.18% |
| Q1 2012 | 2012-03-31 | $350.0M | $42.0M | +13.64% |
| Q4 2011 | 2011-12-31 | $401.0M | $106.0M | +35.93% |
| Q3 2011 | 2011-09-30 | $327.0M | −$10.0M | −2.97% |
| Q2 2011 | 2011-06-30 | $309.0M | −$10.0M | −3.13% |
| Q1 2011 | 2011-03-31 | $308.0M | −$14.0M | −4.35% |
| Q4 2010 | 2010-12-31 | $295.0M | −$11.0M | −3.59% |
| Q3 2010 | 2010-09-30 | $337.0M | $108.0M | +47.16% |
| Q2 2010 | 2010-06-30 | $319.0M | $27.7M | +9.51% |
| Q1 2010 | 2010-03-31 | $322.0M | $40.9M | +14.55% |
| Q4 2009 | 2009-12-31 | $306.0M | — | — |
| Q3 2009 | 2009-09-30 | $229.0M | −$44.8M | −16.36% |
| Q2 2009 | 2009-06-30 | $291.3M | −$14.5M | −4.74% |
| Q1 2009 | 2009-03-31 | $281.1M | — | — |
| Q3 2008 | 2008-09-30 | $273.8M | — | — |
| Q2 2008 | 2008-06-30 | $305.8M | — | — |
Stryker net income trends
Over the last five fiscal years, Stryker's net income increased from $1.60B to $3.25B, a change of $1.65B. The latest reported quarter, Q2 2026, shows $1.28B.
What net income means
Net income is a company’s bottom-line profit or loss after operating costs, interest, taxes, and other reported income and expenses. It shows how much of a company’s revenue ultimately remained as earnings, or how large its loss was, during a fiscal period.
SEC-reported net income
TickerStat standardizes consolidated net income or profit and loss reported in company SEC filings for aligned fiscal periods. It is not adjusted earnings, an analyst estimate, or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Stryker source filings ↗Community posts
Stryker completes ZuriMED acquisition to broaden its shoulder-repair offering
Stryker ($SYK) completed its acquisition of privately held ZuriMED, adding FiberLocker technology to its sports medicine business. The commercialized product is used to augment rotator cuff repair and is designed to increase the mechanical ...